Erratum: Deficiency of interleukin-1 receptor antagonist induces aortic valve disease in BALB/c mice (Arteriosclerosis, Thrombosis, and Vascular Biology (2010) 30 (708-715) DOI: 10.1161/ATVBAHA.109.201749);Deficiency of interleukin-1 receptor antagonist induces aortic valve disease in BALB/c Mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 4, 2010, Pages 708-715

  Isoda, Kikuo ^a   Matsuki, Taizo ^b   Kondo, Harumi ^a   Iwakura, Yoichiro ^b   Ohsuzu, Fumitaka ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Aortic valve stenosis; Cytokine; Immune system; Inflammation; Transplantation

Indexed keywords

CHOLESTEROL; CYTOKINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; CD3 ANTIGEN; IL1RN PROTEIN, MOUSE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE; AORTA VALVE STENOSIS; ARTICLE; CELL TRANSPLANTATION; CYTOKINE PRODUCTION; HISTOLOGY; IMMUNE SYSTEM; INFLAMMATION; LIPID BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; THICKNESS; VALVULAR HEART DISEASE; AGE; AGING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; BONE MARROW TRANSPLANTATION; CELL CULTURE; DOPPLER ECHOCARDIOGRAPHY; ECHOGRAPHY; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MOUSE MUTANT; NUDE MOUSE; TRANSPLANTATION;

AGE FACTORS; AGING; ANIMALS; ANTIGENS, CD3; AORTIC VALVE; AORTIC VALVE STENOSIS; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; ECHOCARDIOGRAPHY, DOPPLER; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIPIDS; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, NUDE; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950889002     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATV.0b013e3181df5488     Document Type: Erratum

References (34)

1. Lindroos M, Kupari M, Heikkala J, Tilvis R. Prevalence of Aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993;21:1220-1225.
2. Stewart BF, Siscovick D, Lind BK, Gardin JM, Gottdiener JS, Smith VE, Kitzman DW, Otto CM. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol. 1997;29: 630-634.
3. Helske S, Kupari M, Lindstedt KA, Kovanen PT. Aortic valve stenosis: an active atheroinflammatory process. Curr Opin Lipidol. 2007;18: 483-491.
4. Kaden JJ, Dempfle CE, Grobholz R, Tran HT, Kilic R, Sarikoc A, Brueckmann M, Vahl C, Hagl S, Haase KK, Borggrefe M. Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis. 2003;170:205-211.
5. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol. 1998;16:457-499.
6. Dinarello CA. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med. 2000; 343:732-734.
7. Matsuki T, Isoda K, Horai R, Nakajima A, Aizawa Y, Suzuki K, Ohsuzu F, Iwakura Y. Involvement of tumor necrosis factor-a in the development of T cell-dependent aortitis in interleukin-1 receptor antagonist-deficient mice. Circulation. 2005;112:1323-1331.
8. Horai R, Asano M, Sudo K, Kanuka H, Suzuki M, Nishihara M, Takahashi M, Iwakura Y. Production of mice deficient in genes for interleukin (IL)-1alpa, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med. 1998;187: 1463-1475.
9. Isoda K, Shiigai M, Ishigami N, Matsuki T, Horai R, Nishikawa K, Kusuhara M, Nishida Y, Iwakura Y, Ohsuzu F. Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation. 2003;108:516-518.
10. Isoda K, Kamezawa Y, Ayaori M, Kusuhara M, Tada N, Ohsuzu F. Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions. Circulation. 2003;107:679-681.
11. Hedrick CC, Castellani LW, Warden CH, Puppione DL, Lusis AJ. Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J Biol Chem. 1993;20676-20682.
12. Isoda K, Kamezawa Y, Tada N, Sato M, Ohsuzu F. Myocardial hypertrophy in transgenic mice overexpressing human interleukin 1a. J Cardiol Fail. 2001;7:355-364.
13. Hoit BD, Khoury SF, Kranias EG, Ball N, Walsh RA. In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency. Circ Res. 1995;77: 632-637.
14. Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I, Sekikawa K, Asano M, Iwakura Y. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity. 2002;17:375-387.
15. Davies PF, Remuzzi A, Gordon EJ, Dewey CF Jr, Gimbrone MA Jr. Turbulent fluid shear stress induces vascular endothelial cell turnover in vitro. Proc Natl Acad Sci USA. 1986;83:2114-2117.
16. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation. 1994;90: 844-853.
17. Ghaisas NK, Foley JB, O'Briain DS, Crean P, Kelleher D, Walsh M. Adhesion molecules in nonrheumatic aortic valve disease: endothelial expression, serum levels and effects of valve replacement. J Am Coll Cardiol. 2000;36:2257-2262.
18. Isoda K, Sawada S, Ishigami N, Matsuki T, Miyazaki K, Kusuhara M, Iwakura Y, Ohsuzu F. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arte-rioscler Thromb Vasc Biol. 2004;24:1068-1073.
19. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605-1612.
20. Aikawa E, Nahredorf M, Sosnovik D, Lok VM, Jaffer FA, Aikawa M, Weissleder R. Multimodality molecular imaging identifies proteolytic and osteogenic activities in early aortic valve disease. Circulation. 2007; 115:377-386.
21. Aikawa E, Whittaker P, Farber M, Mendelson K, Padera RF, Aikawa M, Schoen FJ. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation. 2006;113:1344-1352.
22. Rabkin-Aikawa E, Farber M, Aikawa M, Schoen FJ. Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. J Heart Valve Dis. 2004;13:841-847.
23. Kaden JJ, Kilic R, Sarikoc A, Hagl S, Lang S, Hoffmann U, Brueckmann M, Borggrefe M. Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification. Int J Mol Med. 2005;16:869-872.
24. Kaden JJ, Dempfle CE, Grobholz R, Fischer CS, Vocke DC, Kilic R, Sarikoc A, Pinol R, Hagl S, Lang S, Brueckmann M, Borggrefe M. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol. 2005;14:80-87.
25. Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, Cheng SL, Towler DA. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler Thromb Vasc Biol. 2007;27:2589-2596.
26. Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF. Development and progression of aortic valve stenosis: atherosclerosis risk factors\a causal relationship? A clinical morphologic study. Clin Cardiol. 1991;14:995-999.
27. Novaro GM, Pearce GL, Sprecher DL, Griffin BP. Comparison of cardiovascular risk and lipid profiles in patients undergoing aortic valve surgery vs those undergoing coronary artery bypass grafting. J Heart Valve Dis. 2001;10:19-24.
28. Rajamannan NM, Subramaniam M, Springett M, Sebo TC, Niekrasz M, McConnell JP, Singh RJ, Stone NJ, Bonow RO, Spelsberg TC. Atorva-statin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation. 2002;105: 2660-2665.
29. Rajamannan NM, Subramaniam M, Stock SR, Stone NJ, Springett M, Ignatiev KI, McConnell JP, Singh RJ, Bonow RO, Spelsberg TC. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolemic aortic valve. Heart. 2005;91: 806-810.
30. Rajamannan NM, Subramaniam M, Caira F, Stock SR, Spelsberg TC. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation. 2005;112: I229-I234.
31. Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O'Brien KD. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet. 2002;359:1125-1126.
32. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004; 110:I291-I1295.
33. Moura LM, Ramous SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Goncalves F, Rajamannan NM. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007;49:554-561.
34. Cunningham MW. Autoimmunity and molecular mimicry in the pathogenesis of post-Streptococcal heart disease. Frontiers Biosci. 2003;8: s533-s545.